Biotech: Page 67
-
Lisa Maree Williams via Getty Images
AstraZeneca adds to rare disease drug pipeline with Neurimmune deal
Neurimmune, which will license to AstraZeneca an early-stage treatment for a rare form of cardiomyopathy, is probably best known for its invention of the antibody that became Biogen's Alzheimer's drug Aduhelm.
By Ned Pagliarulo • Jan. 7, 2022 -
Kena Betancur via Getty Images
As three biotechs head to Wall Street, a battered sector braces for a pullback
Amylyx, CinCor and Vigil raised about $480 million combined, a sign of continued investor interest in biotech IPOs. But industry analysts expect fewer and smaller offerings in 2022 due to investor fatigue from high valuations.
By Ben Fidler • Jan. 7, 2022 -
Explore the Trendline➔
Spencer Platt via Getty Images
TrendlineEmerging biotech
New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.
By BioPharma Dive staff -
Novartis turns to Alnylam in research deal aimed at liver failure
The Swiss pharma is familiar with Alnylam's RNA-based technology, which underpins Novartis' newly approved cholesterol drug Leqvio.
By Ned Pagliarulo • Updated Jan. 6, 2022 -
Thomas Lohnes via Getty Images
Pfizer, BioNTech bet mRNA can make a better shingles vaccine
The pharma company, already partnered with BioNTech on vaccines for COVID-19 and influenza, will pay $225 million upfront to further expand its work with the German biotech.
By Ned Pagliarulo • Jan. 5, 2022 -
Getty Images
Avrobio stops work on rare disease gene therapy after unexpected study results
The biotech's gene therapy was one of the furthest along in testing for Fabry, a rare inherited disease that's become a target for drug developers.
By Ned Pagliarulo • Jan. 4, 2022 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.
US pauses distribution of Regeneron, Lilly antibodies over omicron concerns
The decision follows worrisome results in lab studies that indicated omicron can evade both drugs and leaves the U.S. with fewer treatments to respond to the variant's spread.
By Ben Fidler • Updated Jan. 4, 2022 -
Allakos shares plunge as company's top drug falls short in studies
The drug's effect in tissue did not appear to translate to a benefit in reducing symptoms, surprising executives at the biotech as well as its investors.
By Kristin Jensen • Dec. 22, 2021 -
Photo illustration by Maura Sadovi/BioPharma Dive; photograph by Carl Court via Getty Images
Moderna vaccine weaker against omicron, but third shot boosts protection
As a result of new laboratory data, the biotech company is deemphasizing more complex "multivalent" booster shots in favor of further study of its existing formulation and an omicron-specific version.
By Jonathan Gardner • Dec. 20, 2021 -
Getty Images
FDA OKs drugs from Amgen, Argenx, Intra-Cellular in year-end push
The flurry of decisions from the regulator clears for market Amgen and AstraZeneca's asthma treatment Tezspire, Argenx's rare disease drug Vyvgart and Intra-Cellular's Caplyta for bipolar depression.
By Ned Pagliarulo • Dec. 20, 2021 -
Permission granted by Biogen
European regulators say no to Aduhelm, but Biogen is pushing back
The company plans to ask the European Medicines Agency to reexamine its conclusion that "the benefits of Aduhelm do not outweigh its risks."
By Jacob Bell • Dec. 17, 2021 -
Spark expands in Philadelphia, with new facility meant to be Roche's gene therapy hub
The Luxturna developer, now owned by Roche, will invest $575 million to build a huge research and development center on Drexel University's campus.
By Ned Pagliarulo • Dec. 17, 2021 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Image]. Retrieved from https://www.flickr.com/photos/nihgov/49565662436/in/album-72157713108522106/.
Adagio, after bold promises, says antibody drug won't work well against omicron
Shares in the biotech, which raised nearly $500 million to develop a treatment able to neutralize a wide range of coronavirus variants, plummeted on news of the disappointing laboratory test results.
By Kristin Jensen • Dec. 15, 2021 -
Getty Images
Moderna reveals first study results for seasonal flu vaccine
Data from a small Phase 1 trial showed the biotech's vaccine spurred immune responses to four common strains, although they didn't appear significantly greater than an already available shot from Sanofi.
By Ned Pagliarulo • Dec. 10, 2021 -
Courtesy of Eli Lilly
Lilly deepens research ties in China with biotech deal
The collaboration with Regor Therapeutics is another example of large pharma companies' interest in partnering with emerging biotechs from China.
By Ned Pagliarulo • Dec. 10, 2021 -
Sarah Silbiger via Getty Images
FDA panel turns down Reata kidney disease drug in unanimous vote
The company said it will keep working with the FDA ahead of a Feb. 25 decision date, but the committee's verdict greatly diminishes the drug's chances of an approval.
By Kristin Jensen • Dec. 9, 2021 -
Getty Images: Edited by BioPharma Dive
Intercept, awaiting needed trial data, pulls its NASH drug application in Europe
The biotech has lost much of its market value amid delays and regulatory questions for obeticholic acid. But the failures of other drugmakers still leave the company with a chance to rebound.
By Ben Fidler • Dec. 9, 2021 -
Jens Schlueter via Getty Images
Omicron cuts Pfizer vaccine's potency, but data show booster may restore protection
Preliminary laboratory testing by Pfizer and partner BioNTech indicated three doses may protect against omicron as well as two doses versus the original coronavirus strain.
By Ned Pagliarulo , Ben Fidler • Dec. 8, 2021 -
Elizabeth Regan/BioPharma Dive
Acadia shares rise on study success for Rett syndrome drug
The biotech claims the results are enough to pursue an approval, but high rates of side effects and modest efficacy could raise questions about the treatment.
By Ned Pagliarulo • Dec. 7, 2021 -
Christopher Furlong via Getty Images
AstraZeneca wagers $200M on Ionis' next chance at a rare disease drug
The alliance follows AstraZeneca's buyout of Alexion last year and puts the British drugmaker in competition with Alnylam, Bridgebio and several others.
By Ben Fidler • Dec. 7, 2021 -
Permission granted by Odyssey Therapeutics
A serial biotech entrepreneur launches his next startup with high-dollar backing
Founded and led by Gary Glick, Odyssey Therapeutics has raised $218 million in Series A funding for its cancer and inflammatory disease drug research.
By Ned Pagliarulo • Dec. 7, 2021 -
Permission granted by Biohaven Pharmaceuticals
Biohaven to seek FDA approval for second migraine drug after study success
The biotech's drug, called zavegepant, is delivered intranasally and could offer a similar convenience advantage as its first, the fast-selling Nurtec ODT.
By Ned Pagliarulo • Dec. 6, 2021 -
Former Immunomedics executive charged with insider trading around trial data
Usama Malik, chief financial officer of Immunomedics from 2017 to late 2020, is charged with tipping his partner and several relatives of positive study results for the biotech's breast cancer drug.
By Ned Pagliarulo • Dec. 3, 2021 -
Getty / Edited by BioPharma Dive
A startup led by Novartis veteran raises $80M to develop gene therapies for the brain
AviadoBio, which was built around research from the lab of Christopher Shaw at King's College London, is backed by venture firms NEA and Monograph Capital.
By Kristin Jensen • Dec. 2, 2021 -
Getty Images
Facing challenges, Deciphera cuts workforce by a third
The Massachusetts biotech is eliminating 140 positions as it looks to cut costs following disappointing study results for its sole commercial product.
By Kristin Jensen • Dec. 1, 2021 -
Courtesy of Vertex Pharmaceuticals
Vertex, needing research spark, finds promising results in small study of kidney disease drug
The biotech, which has been stung by recent clinical setbacks, plans to soon advance the medicine into late-stage testing.
By Ned Pagliarulo • Dec. 1, 2021
Previous
